At the news
? BULLISHIMPACT 6/10 8-K filed Jul 16, 2026 at 07:00 ET
Insmed reported positive 12-month data from the ongoing open-label extension (OLE) study of TPIP (treprostinil palmitil inhalation powder) in pulmonary arterial hypertension (PAH). The data showed sustained improvements in exercise capacity (6MWD +55.7m for continued TPIP, +54.1m for placebo-crossed), NT-proBNP reduction (~60%), WHO Functional Class, and REVEAL Lite 2.0 mortality risk score, with no new safety signals. These results support the ongoing Phase 3 PALM-PAH trial and strengthen TPIP's profile as a potential best-in-class once-daily inhaled prostanoid.
- 12-month OLE data: mean 6MWD improvement of +55.7 meters (TPIP Continued) and +54.1 meters (Placebo Crossed) from baseline
- NT-proBNP reduced ~60% in both groups (geometric mean ratio 0.40 and 0.41)
- ~80% of patients achieved WHO Functional Class I or II; >25% achieved Class I
- Mean REVEAL Lite 2.0 score improved 2.0 points (Continued) and 1.4 points (Crossed); ~65% of all patients achieved Refined Low Risk status
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access